# Longevity Vision
Longevity Vision is a New York-based venture capital manager that raised two longevity-focused funds, Longevity Vision Fund I LP, and Longevity Vision Fund II LP, between 2019 and 2021, selling a combined $112 million under SEC Form D (SEC filing reporting sales of unregistered securities) filings.[1](https://aum13f.com/firm/longevity-vision-investment-advisors-llc) The funds are managed by Longevity Vision Investment Advisors LLC, registered at 555 [Madison Avenue](https://www.edgepedia.org/madison-avenue), 5th Floor, New York, NY 10022.[2](https://aum13f.com/fund/longevity-vision-fund-ii-lp) The firm describes itself as a longevity biotech holding developing therapies for age-related diseases by focusing on the pathways of aging.[3](https://longevity.vision/portfolio/)
| Fact | Detail |
| --- | --- |
| Manager | Longevity Vision Investment Advisors LLC, 555 Madison Avenue, New York, NY[2](https://aum13f.com/fund/longevity-vision-fund-ii-lp) |
| Funds | Fund I LP (first sale 2019) and Fund II LP (first sale 2021-07-19)[1](https://aum13f.com/firm/longevity-vision-investment-advisors-llc) • [2](https://aum13f.com/fund/longevity-vision-fund-ii-lp) |
| Total sold (Form D) | $112 million ($62.0M Fund I + $50.0M Fund II)[1](https://aum13f.com/firm/longevity-vision-investment-advisors-llc) |
| Focus | Companies extending the period of healthy human life; longevity biotech and health tech[4](https://www.cbinsights.com/investor/longevity-vision-fund) • [3](https://longevity.vision/portfolio/) |
| Filed persons | Directors Dmitry Vorontsov and Vladimir Shilkov on the Form D filings[1](https://aum13f.com/firm/longevity-vision-investment-advisors-llc) |
| Founder (unverified) | Sergey Young, per CB Insights[4](https://www.cbinsights.com/investor/longevity-vision-fund) |
| Last recorded activity | Fund II amendment 2022-03-25; last recorded exit October 2023[1](https://aum13f.com/firm/longevity-vision-investment-advisors-llc) • [4](https://www.cbinsights.com/investor/longevity-vision-fund) |
## Funds, by the numbers
**Longevity Vision Fund I LP** filed its Form D amendment on 2020-04-24, reporting $62.0 million sold and assets under management of $80.7 million. The offering used exemptions 506(b) and 3(c)(1) with a $1,000,000 minimum investment.[1](https://aum13f.com/firm/longevity-vision-investment-advisors-llc) The fund's first sale is recorded as 2019-06-21 in the filing record.[1](https://aum13f.com/firm/longevity-vision-investment-advisors-llc) [CB Insights](https://www.edgepedia.org/cb-insights) lists Fund I as closing April 27, 2020 at $62 million, an early-stage venture fund.[4](https://www.cbinsights.com/investor/longevity-vision-fund)
**Longevity Vision Fund II LP** filed its Form D on 2021-07-30, with a first sale on 2021-07-19. The offering targeted $200.0 million, of which $50.0 million had been sold to 4 investors, leaving $150.0 million remaining, under exemption 506(b) with a $1,000,000 minimum.[2](https://aum13f.com/fund/longevity-vision-fund-ii-lp) An amendment filed 2022-03-25 reported $50.0 million sold and $34.0 million in assets under management.[1](https://aum13f.com/firm/longevity-vision-investment-advisors-llc) The Form D filings do not name the limited partners.
On the filed record, Fund II's $200 million target was exactly one quarter subscribed.[2](https://aum13f.com/fund/longevity-vision-fund-ii-lp)
## People
The Form D filings name Dmitry Vorontsov and Vladimir Shilkov as directors. Vorontsov appears as a director on 16 Form D filings across 3 firms between 2011 and 2026, plus one filing as an executive officer under the spelling "Voronstov"; Shilkov appears as a director on 1 filing for 1 firm.[1](https://aum13f.com/firm/longevity-vision-investment-advisors-llc) Both are listed as directors on Fund II's filings.[2](https://aum13f.com/fund/longevity-vision-fund-ii-lp)
The leadership picture is not fully resolved. CB Insights, an unverified directory, lists Sergey Young, with work history at [McKinsey & Company](https://www.edgepedia.org/mckinsey-and-company), as the fund's founder.[4](https://www.cbinsights.com/investor/longevity-vision-fund)
## Strategy and portfolio
The fund's stated strategy is to invest in companies that provide products, services, and technologies aimed to extend the period of healthy human life.[4](https://www.cbinsights.com/investor/longevity-vision-fund)
CB Insights records 10 investments, the latest being [Senda Biosciences](https://www.edgepedia.org/senda-biosciences)' $123 million Series C on August 16, 2022. Other recorded rounds include [Tessera Therapeutics](https://www.edgepedia.org/tessera-therapeutics)' $300 million Series C on April 19, 2022 and Biolinq's $100 million Series B on September 15, 2021.[4](https://www.cbinsights.com/investor/longevity-vision-fund) These figures come from an unverified directory and are not corroborated by primary filings in the evidence set.
The firm's own portfolio page names founders including [David Kirn](https://www.edgepedia.org/david-h-kirn), David Schaffer, Theresa Janke and Melissa Kotterman, and separately David Sinclair and Tristan Edwards, though the page does not make fully clear which companies these founders correspond to.[3](https://longevity.vision/portfolio/)
## Exits and recent developments
CB Insights records 3 exits: the merger of Senda Biosciences into Sail Biomedicines on October 19, 2023, and two IPOs on December 11 and December 4, 2020.[4](https://www.cbinsights.com/investor/longevity-vision-fund) The IPO companies are not named in the retrieved evidence.
On the filing record, no new fund filings appear after 2022: the most recent Form D activity is Fund II's 2021-07-30 filing and its 2022-03-25 amendment.[1](https://aum13f.com/firm/longevity-vision-investment-advisors-llc) Combined with the October 2023 merger as the last recorded exit, the firm's public record through September 2026 is quiet.
## References
1. Longevity Vision Investment Advisors LLC | AUM 13F — https://aum13f.com/firm/longevity-vision-investment-advisors-llc
2. Longevity Vision Fund II LP | AUM 13F — https://aum13f.com/fund/longevity-vision-fund-ii-lp
3. Investment Portfolio – Longevity Vision Holding — https://longevity.vision/portfolio/
4. Longevity Vision Fund Portfolio Investments, Funds, Exits (CB Insights) — https://www.cbinsights.com/investor/longevity-vision-fund
---
*Topic: Encyclopedia › Society and history › Economics and business › Finance › Venture capital and private equity › Venture capital firms of the Americas › Healthcare and life sciences investors › Biopharma and biotech investors*
*Initially written Sep 17, 2026 · Edited: Oct 11, 2026; Oct 15, 2026*
*Copyright 2026 EdgeChat AI, a subsidiary of Biostate AI.*
License: Edgepedia Community License 1.0, https://www.edgepedia.org/edgepedia/license